Talis Biomedical Corp. (TLIS): Price Target Chart

The current market value of Talis Biomedical (TLIS) shown on this chart is currently 5.02. The business is optimizing sample delivery through rapid tests, which increases profit for medical centers. The Talis One system ensures high accuracy for infection analysis directly within the clinic. However, management is currently liquidating the company due to a failed strategy, and investors have completely lost faith in the asset.

Talis Biomedical Corp (TLIS): Price Target Chart from 07/04/2022 to 09/07/2024

Analytical breakdowns for Talis Biomedical (TLIS)

- stock quotes and analyst forecast:

Price talis.bio|TLIS - Price Target Chart

- stock exchange capitalization data:

Market Value Talis Biomedical Corp|TLIS - Enterprise Value

- issuer book value statistics:

Net Assets per Share Talis Biomedical|TLIS - Company Book Value|Market Capitalization to Book Value talis.bio|TLIS - Company Total Assets

- debt obligations and liquidity statistics:

- net income and valuation ratios data:

TLIS - Company Net Income|Expected Net Profit Talis Biomedical|TLIS - Price to Earnings Ratio|Market Cap to Projected Earnings talis.bio|TLIS - Price/Earnings to Growth Multiple|Enterprise Value to Operating Income Before Depreciation Ratio Talis Biomedical Corp|TLIS - Operating profit EBITDA|Net earnings per share for the last four quarters Talis Biomedical|TLIS - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months talis.bio|TLIS - Net earnings per share growth this year|Expected earnings per share trend next year Talis Biomedical

General company analysis:TLIS Talis Biomedical Corp.

Manufactured products of Talis Biomedical Corp.

The consensus forecast reflects the market's average expectation for the asset's fair value, based on the business's ability to maintain margins under inflationary pressure. By analyzing the aggregate target valuations from investment banks, investors can see how models react to financial reports; for Talis Biomedical (TLIS), this confirms the potential for recurring revenue from the sale of disposable cartridges, which guarantees a stable free cash flow.

Competing companies